الفهرس 
Principles of Stem Cell TransplantationOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Background: Allogeneic hematopoietic stem cell transplantation is is the treatment of choice for a variety of life-threatening diseases e.g. acute leukemia and aplastic anemia. However, HSCT frequently complicated by syndromes characterized by a disruption of the endothelial integrity such as graft-versus-host disease or veno-occlusive disease. Activin-A, a member of the transforming growth factor beta (TGF-β) superfamily, are important for endothelial integrity and tissue repair. TGF is a tumor suppressor induces apoptosis or autophagy, inhibits cell cycle, as well as the expression of cytokines and chemokines. Many mutations in genes encoding receptors and decreased expression of components of the TGF pathway are documented in carcinoma. Activin A has been shown to play dual roles in cancer progression depending on the genetic and cellular context as well as tumor stage, exerting early tumor suppressive and late pro-metastatic effects.
Aim and objectives The aim of the present study was to measure levels of Activin-A in patients underwent allogeneic hematopoietic stem cell transplantation Pretransplant and correlate between serum Activin-A and out comes and with post transplantation complications.
Patients and Methods: Serum Activin-A weas measured using enzyme-linked immunosorbent assay in 30 pre-allogenic bone marrow transplante patients in comparison with 10 healthy controls recruited from the bone marrow transplantation unit, Ain Shams University Hospitals.
Result :Serum level of activin A was elevated in allogenic transplantation patients in comparison with control group, with a statistically significant difference between patients and controls (P<0.001Activin A was positively correlated with chronic graft-versus-host disease (GVHD) and chronic GVHD (P=0.004 and 0.002, respectively)
Conclusion: Activin A level in are useful biomarkers for detection of postallogenic bone marrow transplantation complications.